Pharmaceutical

Vorolanib by EyePoint Pharmaceuticals for Diabetic Macular Edema: Likelihood of Approval

Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Diabetic Macular Edema.

Feb 8, 2024 - 18:00
Vorolanib is under clinical development by EyePoint Pharmaceuticals and currently in Phase II for Diabetic Macular Edema.
Read the original article

Tags:

Previous Article

Monoclonal Antibody Conjugate 3 to Target EGFR for Oncology by ImmunityBio for N...

Next Article

Tapotoclax by Amgen for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Ap...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA warns AstraZeneca over misleading promotional materials for a COPD drug

STAT+: FDA warns AstraZeneca over misleading promotiona...

Aug 15, 2023

Oncoinvent’s Radspherin has FDA fast-track status for ovarian cancer

Oncoinvent’s Radspherin has FDA fast-track status for o...

Jun 26, 2024

STAT+: Pharmalittle: Health care mergers facing tougher antitrust scrutiny; tornado hits Pfizer plant and more shortages may result

STAT+: Pharmalittle: Health care mergers facing tougher...

Jul 20, 2023